Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Lysosomal Acid Lipase Deficiency

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01307098
First received: March 1, 2011
Last updated: July 26, 2016
Last verified: June 2014